Annual income statement for DNA X, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | R2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 54.6 | 69.8 | 93.6 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 6.41 | 11.6 | 19.3 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 92.6 | 83.4 | 93.1 | 3.1 | 5.57 |
| Operating Profit | -38 | -13.6 | 0.513 | -3.1 | -5.57 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -38.5 | -13.9 | 0.284 | -2.88 | -7.96 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -38.6 | -14.1 | -0.09 | -2.88 | -7.96 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -38.6 | -14.1 | -0.09 | -33.6 | -20.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -38.6 | -14.1 | -0.09 | -33.6 | -20.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -735 | -90.2 | -0.024 | -11 | -10.8 |